Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Rivaroxaban

Rivaroxaban Reactions 1704, p335 - 2 Jun 2018 Hepatitis and synthetic liver failure: case report A 39-year-old woman developed hepatitis and synthetic liver failure during treatment with rivaroxaban for deep vein thrombosis (DVT). The woman was commenced on rivaroxaban 20mg daily [route not stated] for deep vein thrombosis of the left peroneus, and developed hepatitis and synthetic liver failure. Her liver function tests were markedly deranged at a clinical review 4 months following the initiation of rivaroxaban. Her ALT, AST, GGT were elevated. ALP was borderline. With the continued elevation in transaminases, synthetic function declined. A liver biopsy showed subacute hepatitis. The presence of multifocal centrilobular perivenular inflammation as well as mononuclear inflammatory infiltrate confirmed the diagnosis of drug-induced liver injury. Rivaroxaban was discontinued after a liver ultrasound confirmed that DVT had resolved. The woman made a rapid recovery thereafter; her laboratory parameters normalised in 4 weeks. Author comment: "We present a case of hepatitis and synthetic liver failure secondary to rivaroxaban". Peverelle M, et al. Drug-induced liver failure due to rivaroxaban. Annals of Hematology 2018: 12 May 2018. Available from: URL: http://doi.org/10.1007/ s00277-018-3364-z - Australia 803322758 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Rivaroxaban

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018

Rivaroxaban

Abstract

Reactions 1704, p335 - 2 Jun 2018 Hepatitis and synthetic liver failure: case report A 39-year-old woman developed hepatitis and synthetic liver failure during treatment with rivaroxaban for deep vein thrombosis (DVT). The woman was commenced on rivaroxaban 20mg daily [route not stated] for deep vein thrombosis of the left peroneus, and developed hepatitis and synthetic liver failure. Her liver function tests were markedly deranged at a clinical review 4 months following the initiation of...
Loading next page...
 
/lp/springer_journal/rivaroxaban-0YQ90pAJnb
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46978-z
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p335 - 2 Jun 2018 Hepatitis and synthetic liver failure: case report A 39-year-old woman developed hepatitis and synthetic liver failure during treatment with rivaroxaban for deep vein thrombosis (DVT). The woman was commenced on rivaroxaban 20mg daily [route not stated] for deep vein thrombosis of the left peroneus, and developed hepatitis and synthetic liver failure. Her liver function tests were markedly deranged at a clinical review 4 months following the initiation of rivaroxaban. Her ALT, AST, GGT were elevated. ALP was borderline. With the continued elevation in transaminases, synthetic function declined. A liver biopsy showed subacute hepatitis. The presence of multifocal centrilobular perivenular inflammation as well as mononuclear inflammatory infiltrate confirmed the diagnosis of drug-induced liver injury. Rivaroxaban was discontinued after a liver ultrasound confirmed that DVT had resolved. The woman made a rapid recovery thereafter; her laboratory parameters normalised in 4 weeks. Author comment: "We present a case of hepatitis and synthetic liver failure secondary to rivaroxaban". Peverelle M, et al. Drug-induced liver failure due to rivaroxaban. Annals of Hematology 2018: 12 May 2018. Available from: URL: http://doi.org/10.1007/ s00277-018-3364-z - Australia 803322758 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References